"Hematinics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias.
| Descriptor ID |
D006397
|
| MeSH Number(s) |
D27.505.954.502.543
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hematinics".
Below are MeSH descriptors whose meaning is more specific than "Hematinics".
This graph shows the total number of publications written about "Hematinics" by people in this website by year, and whether "Hematinics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 5 | 0 | 5 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 0 | 3 |
| 2010 | 11 | 1 | 12 |
| 2011 | 1 | 1 | 2 |
| 2012 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hematinics" by people in Profiles.
-
Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2023 07 31; 38(8):1890-1897.
-
The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int. 2023 06; 103(6):1180-1192.
-
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D). Am J Nephrol. 2023; 54(1-2):1-13.
-
The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170.
-
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 09; 17(9):1325-1336.
-
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602.
-
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972.
-
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335.
-
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324.
-
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315.